AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
384.60B
Market cap384.60B
Price-Earnings ratio
103.56
Price-Earnings ratio103.56
Dividend yield
2.97%
Dividend yield2.97%
Average volume
4.67M
Average volume4.67M
High today
$219.60
High today$219.60
Low today
$214.31
Low today$214.31
Open price
$219.60
Open price$219.60
Volume
5.16M
Volume5.16M
52 Week high
$221.77
52 Week high$221.77
52 Week low
$163.81
52 Week low$163.81

ABBV News

TipRanks 21h
AbbVie price target raised to $245 from $215 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on AbbVie (ABBV) to $245 from $215 and keeps an Overweightrating on the shares. AbbVie ann...

Simply Wall St 3d
Assessing AbbVie Valuation After Rinvoq Exclusivity Extension Secures Key Revenue Driver

If you are trying to figure out what to do with your AbbVie (ABBV) shares, the most recent development might catch your eye. The company just settled with gener...

Assessing AbbVie Valuation After Rinvoq Exclusivity Extension Secures Key Revenue Driver
TipRanks 5d
AbbVie’s ABBV-1088 Study: A Closer Look at Recent Developments

Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...

Analyst ratings

61%

of 31 ratings
Buy
61.3%
Hold
35.5%
Sell
3.2%

More ABBV News

TipRanks 5d
‘Really Long Runway’: AbbVie Stock Jumps afer Settlement on Anti-Inflammatory Drug

The shares of AbbVie (ABBV) climbed nearly 5% on Thursday morning after the American drugmaker reached a settlement with manufacturers producing “generic” or ch...

Seeking Alpha 5d
AbbVie settles with generic drugmakers for key immunology drug Rinvoq

Healthcare AbbVie settles with generic drugmakers for key immunology drug Rinvoq Sep. 11, 2025 8:01 AM ET AbbVie Inc. (ABBV) Stock By: Dulan Lokuwithana, SA New...

AbbVie settles with generic drugmakers for key immunology drug Rinvoq
TipRanks 5d
AbbVie Settles to Delay RINVOQ Generics Until 2037

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.